10-Q: Fortress Biotech Reports First Quarter 2024 Financial Results, Highlights Pipeline Progress

Fortress Biotech's Q1 2024 results show a net loss of $15.4 million, with revenue driven by dermatology product sales and ongoing development of its biopharmaceutical pipeline.

Summary

• Fortress Biotech reported a net loss attributable to Fortress of $15.4 million for the first quarter of 2024, compared to a net loss of $21.5 million in the same period of 2023.
• The company's net revenue for Q1 2024 was $13.0 million, primarily driven by product revenue from Journey Medical Corporation's dermatology portfolio.
• Operating expenses totaled $49.6 million, which included research and development costs of $24.8 million.
• The company's cash and cash equivalents were $83.8 million as of March 31, 2024.
• Fortress Biotech continues to advance its biopharmaceutical pipeline, with several product candidates in clinical development.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in the pipeline and revenue growth in dermatology, the company is still operating at a loss and faces significant risks and challenges. The complete response letter for cosibelimab is a setback, and the need for additional funding is a concern. Overall, the sentiment is neutral to slightly negative.

Positives

• Journey Medical's dermatology product sales increased by 7% year-over-year, indicating strong performance in that segment.
• The FDA accepted the NDA for DFD-29, setting a PDUFA goal date, which is a positive step towards potential approval.
• The company has a robust pipeline with several product candidates in clinical development, including cosibelimab, Triplex, MB-106, and dotinurad.
• Fortress Biotech has a cash balance of $83.8 million, providing a financial runway for ongoing operations and development activities.
• The company is expanding its pipeline into new therapeutic areas, such as autoimmune diseases with MB-106.

Negatives

• The company reported a net loss of $15.4 million for the quarter, indicating ongoing financial challenges.
• Checkpoint Therapeutics received a complete response letter for its cosibelimab BLA, citing manufacturing issues, which will delay potential approval.
• The company's operating expenses remain high at $49.6 million, including significant research and development costs.
• The company is reliant on third-party manufacturers, which introduces risks related to supply chain and quality control.
• A significant portion of Journey's sales come from products without patent protection, making them vulnerable to generic competition.

Risks

• The company's product candidates are subject to lengthy and costly regulatory approval processes, with no guarantee of success.
• The company relies heavily on third-party manufacturers, which could lead to supply chain disruptions or quality control issues.
• The company faces intense competition in the biotechnology and pharmaceutical industries, which could limit the commercial success of its products.
• The company has a history of operating losses and may not achieve profitability in the near future.
• The company's debt obligations could restrict its operations and ability to raise additional capital.
• The company's products may not achieve broad market acceptance, limiting their commercial potential.
• The company is subject to various healthcare laws and regulations, which could lead to penalties or sanctions for non-compliance.
• The company's intellectual property rights may be challenged or invalidated, allowing competitors to develop similar products.
• The company's reliance on third-party data and results could lead to inaccurate assumptions and conclusions.
• The company's reliance on third-party contract research organizations and site management organizations could lead to delays or failures in clinical trials.

Future Outlook

The company expects to continue to incur substantial losses for the next several years as it continues to fully develop and prepare regulatory filings and obtain regulatory approvals for its existing and new product candidates. The company will need to raise additional funding through strategic relationships, public or private equity or debt financings, sale of partner companies, grants or other arrangements to develop and prepare regulatory filings and obtain regulatory approvals for the existing and new product candidates, fund operating losses, and, if deemed appropriate, establish or secure through third parties manufacturing for the potential products, sales and marketing capabilities.

Management Comments

• The parent Company's current cash and cash equivalents of $43.9 million are sufficient to fund the parent entity and private subsidiary operations for at least the next 12 months.
• The Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, sale of partner companies, grants or other arrangements to develop and prepare regulatory filings and obtain regulatory approvals for the existing and new product candidates, fund operating losses, and, if deemed appropriate, establish or secure through third parties manufacturing for the potential products, sales and marketing capabilities.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory processes, and intense competition. Fortress Biotech's Q1 2024 results reflect these challenges, with significant R&D spending and ongoing efforts to advance its pipeline. The company's focus on acquiring and developing promising assets aligns with industry trends, but it also faces risks related to clinical trial outcomes, regulatory approvals, and market acceptance.

Comparison to Industry Standards

• Fortress Biotech's Q1 2024 net loss of $15.4 million is comparable to other development-stage biopharmaceutical companies that are investing heavily in R&D.
• The company's reliance on third-party manufacturers is a common practice in the industry, but it also introduces risks related to supply chain and quality control.
• The company's focus on dermatology products through Journey Medical is a strategic move to generate revenue while advancing its pipeline.
• The company's cash balance of $83.8 million is relatively strong compared to other companies of similar size, but it will need to raise additional capital to fund its long-term growth plans.
• The company's pipeline includes several promising product candidates, such as cosibelimab, DFD-29, and Triplex, which are in various stages of clinical development, similar to other companies in the sector.
• The company's reliance on licensing agreements is a common practice in the industry, but it also introduces risks related to disputes with licensors and the terms of such agreements.
• The company's strategy of acquiring and developing assets is similar to other companies in the sector, but it also faces risks related to integrating acquired businesses and technologies.

Legal Proceedings

• Caelum Biosciences, Inc. is the defendant in a lawsuit brought by The University of Tennessee Research Foundation, with Fortress having indemnification obligations under certain circumstances.

Related Party Transactions

• The company has entered into Founders Agreements and Management Services Agreements with certain of its subsidiaries and partner companies.
• The company has a shared services agreement with TG Therapeutics, Inc. and Journey Medical Corporation.
• The company has a desk share agreement with TG Therapeutics, Inc.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity raises and potential losses due to the company's ongoing operating losses.
• Employees may be affected by potential cost-cutting measures or changes in the company's strategy.
• Customers of Journey Medical may be affected by changes in product availability or pricing.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• The company intends to seek to address the feedback in a potential BLA resubmission for cosibelimab, which is currently targeted for mid-year.
• The company expects data from the Phase 1b clinical trial for dotinurad in Q3 2024.
• The company anticipates topline data from the Phase 2 clinical trial for Triplex in Q4 2024.
• The company plans to initiate a Phase 1 investigator-sponsored clinical trial evaluating MB-106 in autoimmune diseases in Q4 2024.
• The company expects topline data for the Phase 1b/2a clinical trial of AJ201 in SBMA midyear 2024.

Key Dates

Keywords

biopharmaceutical, dermatology, clinical trials, product development, regulatory approval, oncology, immunotherapy, CAR T-cell therapy, gout, Menkes disease